No Data
Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data From Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Raises Target Price to $44
Buy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety Profile
Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection With Public Offering of Common Stock
Mineralys Therapeutics Insider Bought Shares Worth $8,100,000, According to a Recent SEC Filing